Pharmsville Co. Ltd (318010) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Pharmsville Co. Ltd stock KRW 5,100, price KRW 3,390, upside +50.5%, quality 66 out of 100. Rating: strongly undervalued. Calculated from audited financials with 18 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 3,107 KRW – 17,223 KRW · fair‑value band 3,366 KRW – 6,375 KRW · the 3,390 KRW price screens below the 5,100 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Pharmsville Co. in your weekly email
Every Wednesday you see whether Pharmsville Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Pharmsville Co., Ltd. produces and sells functional health food in South Korea. The company also exports its products. It offers its products under the Apple Tree Dr. Kim, Devil Diet, Sang Sang Bang, Vitamin Story, Apple Tree, Golden Garden, Daily Green, Wilac, Doctor Solution, and PS brands.
Show moreShow less
Pharmsville Co., Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.
Stock analysis
Pharmsville Co. Ltd (318010) currently trades at 3,390 KRW, while our model-based Fair Value estimate is 5,100 KRW, implying the stock looks roughly 34% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 6,994 KRW per share, and 11 of the 18 models we run sit above the 3,390 KRW price.
Bear case: the Dividend Discount group reads lowest at 1,094 KRW, and 7 of the 18 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 3,366 KRW (bear) to 6,375 KRW (bull), the price of 3,390 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Pharmsville Co. Ltd reported revenue of 12.7B KRW in FY2025 versus 39.0B KRW in FY2021, a compound −24.4%/yr. Reported net income was 2.9B KRW in FY2025, compounding −12.8%/yr from FY2021.
Key figures
Market cap 26.2B KRW (≈ $19.4M) Micro · P/E ratio 8.9 · P/S ratio 2.34 · EPS (TTM) 386.80 KRW · Dividend yield 5.9% · Net margin 26.7% · Return on equity 4.6% · Return on assets (EBIT) 2.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 50%, 318010 screens cheaper than that median.
Fair Value models
Bear3,366 KRWFair Value 5,100 KRWBull6,375 KRW
Price 3,390 KRW · Upside +50.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (160.19 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−23.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−21.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−20.2%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.4%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−4.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−10.1%
Dividend (yield on the price)5.9%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → −5%
⚠ Revenue per share shrinking 17.8%/yr over ~6Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
The company could shrink this much every year for the next five years and today's price would still be justified.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score66 · Top 25%
Fair Value upside+50.5% · Top 25%
Profitability
Return on equity (12 months)4.6% · Below median
Return on assets4.2% · Above median
Net margin (12 months)26.7% · Top 25%
Operating margin (12 months)−6.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−22.1% · Bottom 25%
Dividend yield (12 months)5.9% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)8.9× · Cheapest 25%
P/B0.39× · Cheapest 25%
P/S (12 months)2.34× · Pricier than median
Price / free cash flow (fiscal year)14.4× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Pharmsville Co. Ltd (318010) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 5,100 KRW versus a price of 3,390 KRW, about +50% upside (undervalued).
What is the fair value of 318010?
Our model-based fair value for Pharmsville Co. Ltd is 5,100 KRW (as of Nov 3, 2026), built from audited fundamentals. The current price: 3,390 KRW.
What is the quality score of 318010?
Pharmsville Co. Ltd has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pharmsville Co. Ltd (318010)?
Our model-based price target is the fair value of 5,100 KRW (as of Nov 3, 2026) from 18 valuation models. Cautious scenario 3,366 KRW, optimistic scenario 6,375 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Pharmsville Co. Ltd stock forecast for 2026?
Our models put fair value at 5,100 KRW, about +50% upside versus a price of 3,390 KRW (undervalued). Cautious scenario 3,366 KRW, optimistic scenario 6,375 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Pharmsville Co. Ltd (318010)?
Pharmsville Co. Ltd reported trailing-twelve-month revenue of about 11.2B KRW (latest available figure, as of Nov 3, 2026).
Does Pharmsville Co. Ltd pay a dividend?
Pharmsville Co. Ltd currently shows a dividend yield of 5.90% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of Pharmsville Co. Ltd (318010) and when is the ex-dividend date?
Pharmsville Co. Ltd pays a dividend of 200.00 KRW per share a year, a dividend yield of 5.9%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 2019. The payout ratio is 51.7% of earnings. Free cash flow covers the dividend 1.18 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Pharmsville Co. Ltd (318010)?
For today's price to be fair in a discounted-cash-flow model, Pharmsville Co. Ltd would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -20.2 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of 318010 use?
Our models discount Pharmsville Co. Ltd at 8.9 %: a base by market capitalisation (nano), damped by beta 0.15, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Pharmsville Co. Ltd that is less than minus 40 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Pharmsville Co. Ltd (318010) delivered so far?
Over the past 5 years revenue at Pharmsville Co. Ltd grew -20.2 % a year. The price currently implies free-cash-flow growth of less than minus 40 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Pharmsville Co. Ltd (318010) growing?
The median revenue growth in the sector is +14.3 % a year. That is the yardstick for the growth priced into Pharmsville Co. Ltd (less than minus 40 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Pharmsville Co. Ltd (318010)?
The free-cash-flow yield on the price is 6.96 %: that much free cash flow Pharmsville Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Pharmsville Co. Ltd (318010)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pharmsville Co. Ltd it is 5,100 KRW per share (as of Nov 3, 2026), against a price of 3,390 KRW. It is the blended result of 18 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Pharmsville Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 318010 trades below its calculated fair value: price 3,390 KRW, fair value 5,100 KRW, a gap of about +50% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 318010?
No. The price is what the market pays today (3,390 KRW); the fair value is what the company's own numbers justify (5,100 KRW). For Pharmsville Co. Ltd the two are 1,710 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Pharmsville Co. Ltd worth?
The market values Pharmsville Co. Ltd at about 26.2B KRW (market capitalisation, as of Nov 3, 2026). Per share that is 3,390 KRW; our models calculate a fair value of 5,100 KRW per share.
What do the bullish and bearish scenarios say about 318010?
Our models span a range for Pharmsville Co. Ltd: cautious scenario 3,366 KRW, base 5,100 KRW, optimistic 6,375 KRW per share (as of Nov 3, 2026, price 3,390 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 318010?
Pharmsville Co. Ltd trades at a price-to-earnings ratio of 8.9 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 5,100 KRW is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2019 to 2025), reported earnings: 20.3. Other multiples: P/B 0.4, P/S 2.3.
How solid is the balance sheet of Pharmsville Co. Ltd (318010)?
Balance-sheet figures for Pharmsville Co. Ltd (as of Nov 3, 2026): return on equity 4.6%. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is 318010 from its 52-week high?
Pharmsville Co. Ltd trades at 3,390 KRW, about 13% below its 52-week high of 3,885 KRW and 6% above the low of 3,192 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 5,100 KRW is for.
Which stocks are comparable to Pharmsville Co. Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pharmsville Co. Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price 3,390 KRW, calculated fair value 5,100 KRW (+50%), Quality Score 66/100, from 18 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 318010 calculated?
We run Pharmsville Co. Ltd through 18 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 5,100 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Pharmsville Co. Ltd currently trades 34% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pharmsville Co. Ltd (318010)?
The closing price on Nov 6, 2026 was 3,390 KRW. Our model-based fair value is 5,100 KRW, about +50% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pharmsville Co. Ltd right now?
Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (3,366 KRW to 6,375 KRW) leaves room in how you read the outcome.
Key figures of Pharmsville Co. Ltd
How large is the market capitalisation of Pharmsville Co. Ltd (318010)?
The market capitalisation of Pharmsville Co. Ltd is 26.2B KRW (≈ $19.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pharmsville Co. Ltd (318010)?
The price-to-sales ratio of Pharmsville Co. Ltd is 2.34 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pharmsville Co. Ltd (318010)?
Earnings per share at Pharmsville Co. Ltd are 386.80 KRW (price ÷ EPS = P/E 8.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Pharmsville Co. Ltd (318010)?
The dividend yield of Pharmsville Co. Ltd is 5.9% (payout 51.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Pharmsville Co. Ltd (318010)?
The net margin of Pharmsville Co. Ltd is 26.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pharmsville Co. Ltd (318010)?
The return on equity (ROE) of Pharmsville Co. Ltd is 4.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pharmsville Co. Ltd (318010)?
On an EBIT basis the return on assets of Pharmsville Co. Ltd is 2.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pharmsville Co. Ltd (318010)?
The operating margin of Pharmsville Co. Ltd is −6.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pharmsville Co. Ltd (318010)?
Revenue at Pharmsville Co. Ltd is growing −22.1% versus a year earlier (3y avg −21.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Pharmsville Co. Ltd (318010)?
Earnings per share at Pharmsville Co. Ltd are growing +0.1% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Pharmsville Co. Ltd in the live analysis
One click puts Pharmsville Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 3, 2026